What is going on with this biotech stock? How can the company fail its Phase 3 trial for its lead drug, pushing the stock price down instantly from $45 a share to $8 a share, and then go up 50%? In this case, the answer is becoming clearer: The trial shouldn’t have failed. It was flawed.
The post This Biotech Company is on the Move, So Buy Again appeared first on Agora Financial.